NCT00140452

Phase II Study Using Thalidomide for the Treatment of ALS

Phase II Study Using Thalidomide for the Treatment of Amyotrophic Lateral Sclerosis

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 24 (estimated)
• Sponsor: Dartmouth-Hitchcock Medical Center · Academic / Other
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

The use of Thalidomide in patients with ALS who have disease progression.

Detailed description

Phase II open labeled trial testing the efficacy of thalidomide for ALS in the setting of disease progression.

Conditions

• Amyotrophic Lateral Sclerosis
• ALS

Interventions

Type	Name	Description
DRUG	Thalidomide	Thalidomide will start at a dose of 100mg/day, dose escalated every 2 weeks by 100mg/day to a target dose of 400mg/day.

Timeline

• Start date: 2005-02-01
• Completion: 2007-11-01
• First posted: 2005-09-01
• Last updated: 2007-11-21

Locations

1 site across 1 country: United States